uric acid has been researched along with Mucositis in 3 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Allopurinol is an inhibitor of xanthine oxidoreductase (XOR) and inhibits the generation of uric acid (UA) as the final product of purine catabolism, as well as the resulting generation of superoxide (O2(-)), in humans." | 6.45 | Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? ( Nozaki, S; Onuma, M; Suzuki, I; Yamauchi, T, 2009) |
| "Allopurinol is an inhibitor of xanthine oxidoreductase (XOR) and inhibits the generation of uric acid (UA) as the final product of purine catabolism, as well as the resulting generation of superoxide (O2(-)), in humans." | 2.45 | Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? ( Nozaki, S; Onuma, M; Suzuki, I; Yamauchi, T, 2009) |
| " A dose-response relationship was found for most parameters." | 1.33 | Evidence for predictive validity of blood assays to evaluate individual radiosensitivity. ( Göhde, W; Greve, B; Hacker-Klom, U; Kienast, J; Pascher, E; Severin, E; Silling, G; Wedemeyer, N; Willich, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachmeier, E | 1 |
| Mazzeo, MA | 1 |
| López, MM | 1 |
| Linares, JA | 1 |
| Jarchum, G | 1 |
| Wietz, FM | 1 |
| Finkelberg, AB | 1 |
| Suzuki, I | 1 |
| Yamauchi, T | 1 |
| Onuma, M | 1 |
| Nozaki, S | 1 |
| Severin, E | 1 |
| Greve, B | 1 |
| Pascher, E | 1 |
| Wedemeyer, N | 1 |
| Hacker-Klom, U | 1 |
| Silling, G | 1 |
| Kienast, J | 1 |
| Willich, N | 1 |
| Göhde, W | 1 |
1 review available for uric acid and Mucositis
| Article | Year |
|---|---|
Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?
Topics: Allopurinol; Enzyme Inhibitors; Fatty Liver; Humans; Liver Diseases; Metabolic Syndrome; Mucositis; | 2009 |
2 other studies available for uric acid and Mucositis
| Article | Year |
|---|---|
Mucositis and salivary antioxidants in patients undergoing bone marrow transplantation (BMT).
Topics: Adult; Aged; Bone Marrow Transplantation; Female; Humans; Longitudinal Studies; Male; Middle Aged; M | 2014 |
Evidence for predictive validity of blood assays to evaluate individual radiosensitivity.
Topics: Adolescent; Adult; Cell Cycle; Cytokines; Dose-Response Relationship, Radiation; Feasibility Studies | 2006 |